{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-24-000160","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.759638+00:00","generated_at":"2026-05-29T05:09:38.463513+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nurix: NX-5948 Phase 1 CLL/SLL shows 75.5% ORR, deepens to 84.2%; safe; pivotal trials in 2025","bullets":["ORR 75.5% (n=49) in heavily pretreated CLL/SLL; 84.2% in patients with at least 2 assessments.","Median duration of response not reached; 13 patients >6 months, 5 >1 year on treatment.","Well tolerated; only 1 grade 1 atrial fibrillation; common AEs: purpura/contusion, fatigue, petechiae, neutropenia.","Responses across baseline BTK (38.6%), PLCG2 (12.3%), TP53 (40.4%) mutations and CNS involvement (5 patients).","Company on track to initiate pivotal trials of NX-5948 in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-24-000160","json":"https://secwatch.observer/filing/0001549595-24-000160.json","markdown":"https://secwatch.observer/filing/0001549595-24-000160.md","text":"https://secwatch.observer/filing/0001549595-24-000160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000160/0001549595-24-000160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000160/nrix-20241209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:09:38.463513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}